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~ Eradication therapy against early Pseudomonas aeruginosa 
infection in patients with Cystic Fibrosis 
A.D. Grzejdziak, G. Cimino, S. Benedetti Valentini, V D'AI~, S. Bertasi, 
S. Quattrucci. Uniuersity of Rome "La Sapienza", CF Centre, Department of 
Paediatrics, Italy 
Prevention of chronic Pseudomonas eruginosa (Pa) infection is important in order 
to avoid the progression of lung disease in patients with CE Strategies against early 
Pa infection include patient segregation a d the use of nebulised, oral or intravenous 
antibiotics. The aim of this study was to eradicate the first acquisition of Pa and to 
delay its chronic infection. 
Since December 2002 at our centre 20 patients with CF were treated with oral 
ciprofloxacin (30mg/kg/day for 21 days) plus Tobi ® (300mg twice daily in three 
28-day on/28-day off cycles) for Pa first isolation from oropharyngeal or sputum 
culture. 
We report our experience with 10 patients diagnosed by neonatal screening (6 males, 
4 females, mean age 6 years) who had a mean follow-up of 2.33 years after 
treatment. They had no clinical or radiological signs of lung disease deterioration 
at the time of Pa first isolation and had a good nutritional status. At the end of 
treatment (ciprofloxacin + ToN ® in 3 cycles) all patients were free from Pa as 
assessed by negative respiratory culture; 8 patients had negative culture soon after 
1 month of therapy. During 2 year of follow-up all but two patients remained free 
from Pa. In 2 patients putum culture grew R aeruginosa at months 7 and 18; they 
were treated again with ciprofloxacin + ToN ® and during 1 year of follow-up they 
had no positive culture for Pa. The treatment was well tolerated and no adverse 
event related to the treatment was reported. 
Treatment of first isolation of Pa seems to delay the onset of chronic infection. 
Further studies and a long follow-up are needed to understand if progression of 
CF lung disease that usually accompanies chronic infection can be delayed. 
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I~A retrospective study to assess the response to nebulised 
salbutamol during a period of stability in adult patients with 
Cystic Fibrosis 
T. Hughes, hJ. Clifton, D.G. Peckham, C. Etherington, K. Pollard, S.R Conway. 
Leeds' Adult Cystic Fibrosis Unit, UK 
Aims: Nebulised f3 agonists are the most commonly prescribed agents for progres- 
sive airways obstruction in cystic fibrosis (CF) although studies showing benefit 
are underpowered. The aims of the study were to assess prevalence of airways 
reversibility to salbutamol within a population of stable adult patients and to 
determine if reversibility is linked to specific patient characteristics. 
Method: At annual assessment reversibility trials were undertaken according to a 
protocol adapted from BTS guidelines. A significant response to salbutamol was 
defined as >15% increase in FEV1. Demographic data recorded were total serum 
IgE, Aspergillus pecific IgE, eosinophil count, sputum microbiology, genotype, 
maintenance treatment, age, body mass index (BMI), gender and spirometry values 
pre and post nebulised Salbutamol. Data were analysed using the Mann-Whitney 
and Chi-Square tests (SPSS). A p value of <0.05 was regarded as significant. 
Results: A total of 83 patients completed reversibility trial to nebulised salbutamol 
during the study period. 15 patients (18.1%) showed significant response to 
reversibility esting. The main predictive factor was lower pre-existing lung function. 
The median (range) FEV1% was 39% (22 72) and 54.5% (24 91) for the patients 
with a positive response to salbutamol and no response respectively (Mann-Whitney 
p < 0.05). There were no significant differences between the two groups for other 
demographics analysed; total serum IgE, Aspergillus pecific IgE, eosinophil count, 
age and BMh 
Conclusion: Patients with CF, especially those with lower lung function, may show 
significant response to salbutamol. Further studies are required to identify optimal 
dose and delivery during disease stability and exacerbation. 
• Clinical evolution of Cystic Fibrosis patients in diary treatment 
for four years with rhDNase 
I. Largo 1,2, C. Gonz~lez 1 , J. Lozano 2. 1 Uniuersidad e Chile, 2Hospital Roberto 
del Rio, Chile 
The Cystic Fibrosis (CF) treatment with rhDNase has been widely reported. The 
success of its use implies the early diagnosis, previous to the damage of pulmonary 
structure. Up to this day, in our hospital, the rhDNase is been used on those patients 
who have severe chronic disease, with established pulmonary deterioration. 
Material and method: 15 patients with CE 10 men (67%), mean age 13 years 
6 months. All of them with severe disease, diary they have been using rhDNase, 
2.5 mg (2.5 ml) with ProNeb Compressor and Pari LC jet (+). The patient has been 
followed for four years. 
Clinical story: 100% had repetitive obstructive bronchitis yndrome, 80% repetitive 
bronchopneumonia, 27% malnutrition and 73% pansinusitis. 
Post two years in treatment we find: the BMI 6.6% malnutrition,13.4% in risk, 
66.6% normal, 13.3% overweight and 0% obesity. Post four years in treatment: 0% 
malnutrition, 20% in risk, 46.7% normal, 20% overweight and 13.4% obesity. The 
pulmonary function FEV1 had fallen from 72.1% to 56.5%. The bronchial microbi- 
ology shows post two year in treatment: 6.6% negative, 60% Staphylococcus aureus 
(SA), 6.6% SA meticiline resistant (MRSA), 26.7% Pseudomonas eruginosa (PA) 
and 13.3% positive to another. Post four years in treatment: 33.3% were negative, 
13.3% SA, 0% MRSA, 26.7% PA, 26.7% another bacterial. 
Conclusions: 
These patients demonstrate an improvement in nutritional and microbiological 
condition after a four-year treatment. 
The deterioration of the pulmonary function continues. 
We think that the early use of rhDNase, previous to the chronic damage pul- 
monary established, would avoid this deterioration, since the other two elements 
that play a fundamental roll in the pulmonary damage, nutritious state and 
infections, have improved with their use. 
1• Prevention of respiratory syncytial virus (RSV) infection in 
CF infants 
A. Miano 1 , M. Ambroni 1, P.L. Grzincich 2, G. Pisi 2, R. Casciaro 3, A. De Alessandri 3, 
R Moretti 4, E. Bignamini 5, M. Castello 5. 1Centre FC, Cesena; 2Centre FC, Parma; 
3Centre FC, Genoua; 4Centre FC, Teramo; 5Centre FC, Torino, Italy 
Aims: Viral pulmonary infections may be harmful in CF infants. RSV is causing 
up to 50% of total vires pulmonary infections in the winter season. Palivizumab, 
a humanized immunoglobulin monoclonal antibody, is considered to be a safe and 
effective preventive measure of RSV infection in high-risk infants. Unfortunately no 
RCT is carried out in CF patients, and there is some uncertainty in suggesting such 
expensive drag. We carried out a prospective study in CF infants receiving Palivizumab 
prophylaxis in order to evaluate some clinical outcomes. 
Method: 33 CF infants (<24 months of age; M 16/33) attending at our CF Centers 
underwent he RSV prophylaxis. All infants were given a dose of 15mg/Kg by 
intramuscular injection every 30 days from November 2004 to March 2005 and followed 
up to April 30 2005. The infants were assessed accordingly to standard protocols and 
evaluated at each exacerbation during the period of prophylaxis. The Now RSV Test 
(Binax) was performed to detect RSV at each clinical exacerbation. 
Results: are reported in table 1. 
Table 1 
No. of h~Fants 33 
Medium age, months 10.8 (222) 
Total mild pulmonary exacerbations 11 
No. of mild exacerbation n each month Nov 1, Dec 1, Jan 5, Feb 1, Mar 3 
Total severe pulmonary exacerbations 2 
Now RSV test ire in patient with all puhnonary exacerbations 13 
No. of hospital dmissions 2 
No. of days of hospitalization 23 
Rate of hospital dnfission 2/33 (6%) 
No. of puhnonary complications 0 
No. of adverse r actions 0 
Condusions: Palivizumab seems to be safe and effective for preventing severity of RSV 
infection and Hospital admissions. For more data to be provided further investigations 
would be required. 
